Overview

A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2017-07-07

Target enrollment:

Participant gender:

Summary

The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.

Phase:

Phase 1

Details

Lead Sponsor:

Taiho Oncology, Inc.

Collaborator:

Quintiles, Inc.

Treatments:

Capecitabine